Aptevo

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Aptevo and other ETFs, options, and stocks.

About APVO

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. 

CEO
Jeffrey G. Lamothe
CEOJeffrey G. Lamothe
Employees
36
Employees36
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2016
Founded2016
Employees
36
Employees36

APVO Key Statistics

Market cap
833.97K
Market cap833.97K
Price-Earnings ratio
-0.02
Price-Earnings ratio-0.02
Dividend yield
—
Dividend yield—
Average volume
162.96K
Average volume162.96K
High today
$0.5999
High today$0.5999
Low today
$0.4495
Low today$0.4495
Open price
$0.54
Open price$0.54
Volume
185.18K
Volume185.18K
52 Week high
$25.56
52 Week high$25.56
52 Week low
$0.4495
52 Week low$0.4495

Stock Snapshot

Aptevo(APVO) stock is priced at $0.47, giving the company a market capitalization of 833.97K. It carries a P/E multiple of -0.02.

On 2026-11-17, Aptevo(APVO) stock moved within a range of $0.45 to $0.60. With shares now at $0.47, the stock is trading +4.6% above its intraday low and -21.7% below the session's peak.

Trading activity shows a volume of 185.18K, compared to an average daily volume of 162.96K.

Over the past 52 weeks, Aptevo(APVO) stock has traded between a high of $25.56 and a low of $0.45.

Over the past 52 weeks, Aptevo(APVO) stock has traded between a high of $25.56 and a low of $0.45.

APVO News

TipRanks 22h
Aptevo’s Orphan Drug Status: Limited Exclusivity, Revocation Risks, and Ongoing Competitive Pressure

Aptevo (APVO) has disclosed a new risk, in the Regulation category. Aptevo benefits from an existing orphan drug designation, but this status neither accelerat...

TipRanks 2d
Aptevo Therapeutics provides Q3 business update on Mipletamig

Q3 Business Highlights: Mipletamig delivers a 79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark; Te...

TipRanks 5d
Aptevo Therapeutics Announces Warrant Exercise Financing Agreement

Aptevo Therapeutics ( (APVO) ) just unveiled an announcement. On November 11, 2026, Aptevo entered agreements with certain warrant holders who agreed to exerci...

More APVO News

Seeking Alpha 7d
Aptevo Therapeutics announces exercise of existing warrants for $3M gross proceeds

Aptevo Therapeutics announces exercise of existing warrants for $3M gross proceeds Nov 11, 2026, 9:06 AM ET Aptevo Therapeutics Inc. (APVO) Stock By : Harsh Shu...

Aptevo Therapeutics announces exercise of existing warrants for $3M gross proceeds

People also own

Based on the portfolios of people who own APVO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.